Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

Sponsor

Case Comprehensive Cancer Center (Other)

Overall Status

Terminated

CT.gov ID

NCT00918658

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer.

PURPOSE: This research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.

Condition or Disease	Intervention/Treatment	Phase
Leukemia Multiple Myeloma and Plasma Cell Neoplasm	Other: biologic sample preservation procedure Other: immunologic technique Other: laboratory biomarker analysis

Detailed Description

OBJECTIVES:

To collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays.
To collect information about HLA type and immunophenotype of malignant cells as determined by clinical flow cytometry.

OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.

Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Study Design

Study Type:

Observational

Actual Enrollment :

34 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity

Study Start Date :

Apr 1, 2008

Actual Primary Completion Date :

Mar 1, 2011

Actual Study Completion Date :

Mar 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Patients with hematologic cancer Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma	Other: biologic sample preservation procedure All specimens will be collected using the Pathology Residual Tissue Procurement. Other: immunologic technique Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record. Other: laboratory biomarker analysis Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Patients without cancer Patients who do not have cancer.	Other: biologic sample preservation procedure All specimens will be collected using the Pathology Residual Tissue Procurement. Other: immunologic technique Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record. Other: laboratory biomarker analysis Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.

Arm

Intervention/Treatment

Patients with hematologic cancer

Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma

Other: biologic sample preservation procedure

All specimens will be collected using the Pathology Residual Tissue Procurement.

Other: immunologic technique

Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Other: laboratory biomarker analysis

Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.

Patients without cancer

Patients who do not have cancer.

Other: biologic sample preservation procedure

All specimens will be collected using the Pathology Residual Tissue Procurement.

Other: immunologic technique

Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Other: laboratory biomarker analysis

Outcome Measures

Primary Outcome Measures

Collection of normal and malignant cells to use as target cells in cytotoxicity assays [We anticipate collecting approximately 30 samples in total, over a 1-2 year period.]